Eisai lays out US commercial strategy for high-dose Aricept
This article was originally published in Scrip
Executive Summary
Eisai is aiming for US sales of at least $600 million by 2012 for its new once-daily 23mg tablet formulation of Aricept (donepezil), which has just been approved by the FDA for the treatment of moderate to severe Alzheimer's disease.